Belimumab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Benlysta?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[6] also known as B-lymphocyte stimulator (BLyS).[7] It is approved in the United States[8] and Canada,[9] and the European Union[5] to treat systemic lupus erythematosus and lupus nephritis.[10]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | B-cell activating factor (BAFF, BLyS) |
Clinical data | |
Trade names | Benlysta |
Other names | LymphoStat-B |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611027 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous, subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
Chemical and physical data | |
Formula | C6358H9904N1728O2010S44 |
Molar mass | 144121.90 g·mol−1 |
NY (what is this?) (verify) |
Close
The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).[5]